SEARCH

SEARCH BY CITATION

References

  • 1
    Rebolj M, Ballegooijen MV, Berkers LM, Habbema F. Monitoring a national cancer prevention programme: Successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2006; 120: 80612.
  • 2
    Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, Segnan N. European guidelines for quality assurance in cervical cancer screening. Europe against cancer programme. Eur J Cancer A 1993; 29 ( Suppl 4): S1S38.
  • 3
    Dutch Association of Pathologists. CISOE-A in pictures (in Dutch). CD-Rom. In: HanselaarAGJM, ed. Nijmegen. The Netherlands: University Medical center Nijmegen, 1997.
  • 4
    Patnick J. Cervical cancer screening in England. Eur J Cancer 2000; 36: 22058.
  • 5
    Prismant. Dutch Network and National Database for Pathology (PALGA): results of retrieval action on cervical cytology until 31-03-2004. Utrecht: Prismant, 2004.
  • 6
    Al-Nafussi A, Rebello G, al-Yusif R, McGoogan E. The borderline cervical smear: colposcopic and biopsy outcome. J Clin Pathol 2000; 53: 43944.
  • 7
    Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Verheijen RH, Voorhorst F, van Ballegooijen M, Meijer CJ, Helmerhorst TJ. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005; 116: 1229.
  • 8
    Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB, Bar-Am A. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral. Gynecol Oncol 2000; 79: 17780.
  • 9
    Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A. Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J Med Virol 2003; 69: 11821.
  • 10
    Herrington CS, Evans MF, Hallam NF, Charnock FM, Gray W, McGee JD. Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities. Br J Cancer 1995; 71: 2069.
  • 11
    Pisal N, Sindos M, Chow C, Singer A. Triage by HPV-DNA testing: is it useful in women with persistent minor smear abnormalities? Acta Obstet Gynecol Scand 2003; 82: 5757.
  • 12
    Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. Br Med J 2001; 322: 8934.
  • 13
    Zielinski GD, Snijders PJF, Rozendaal L, Voorhorst FJ, Runsink AP, Schipper FAd, Meijer CJLM. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinicla relevance. J Pathol 2001; 195: 3006.
  • 14
    Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 28093.
  • 15
    Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 2939.
  • 16
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 129.
  • 17
    Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 17823.
  • 18
    Solomon D, Schiffman M. Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst 2004; 96: 2501.
  • 19
    Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J Natl Cancer Inst 2006; 98: 823.
  • 20
    Berkhof J, van Kemenade FJ, Snijders PJ, Verheijen RH, Meijer CJ. When to test women for human papillomavirus: testing is possible without increasing colposcopy referral rate. Br Med J 2006; 332: 237.
  • 21
    Bulk S, Van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 38893.
  • 22
    Dutch Association of Obstetricians and Gynaecologists. Guidelines for treatment of cervical intraepithelial neoplasia, Version 1.1. Available at: http://www.nvog.nl (in Dutch), 2004.
  • 23
    Ballegooijen MV, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. The effects and costs of the cervical cancer screening programme in the Netherlands after the changes (In Dutch). Rotterdam: Erasmus MC, Department of Public Health, 2006.
  • 24
    Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, Verheijen RH, Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testingfor women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 175968.
  • 25
    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 18692.
  • 26
    Skinner EN, Gehrig PA, Van Le L. High-grade squamous intraepithelial lesions: abbreviating posttreatment surveillance. Obstet Gynecol 2004; 103: 48892.
  • 27
    Ballegooijen MV, Koopmanschap MA, Habbema JD. The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands. Eur J Cancer A 1995; 31: 16726.
  • 28
    Prismant. LMR data on hospital admissions 1975–2000. Utrecht, the Netherlands, 2003.
  • 29
    Arbyn M. Triage of women with atypical or low-grade cytological abnormalities of the cervix by HPV testing: systematic review and meta-analysis (Preliminary report). European Network for Cervical Cancer Screening, Brussels: European Network for Cervical Cancer Screening, 2001.
  • 30
    Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006; 195: 34953.
  • 31
    Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94101.
  • 32
    Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 2003; 89: 8349.
  • 33
    Oortmarssen GJV, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991; 64: 55965.
  • 34
    Marcus AC, Crane LA, Kaplan CP, Reading AE, Savage E, Gunning J, Bernstein G, Berek JS. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care 1992; 30: 21630.
  • 35
    Hartz LE, Fenaughty AM. Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 1. Obstet Gynecol 2001; 98: 6749.
  • 36
    Burgers JS, Grol RP, Zaat JO, Spies TH, van der Bij AK, Mokkink HG. Characteristics of effective clinical guidelines for general practice. Br J Gen Pract 2003; 53: 159.
  • 37
    Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005; 92: 9904.
  • 38
    McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. Br J Obstet Gynaecol 2004; 111: 143743.
  • 39
    Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J. Management of the low-grade abnormal Pap smear: what are women's preferences? J Fam Pract 2002; 51: 84955.
  • 40
    Orbell S, Hagger M, Brown V, Tidy J. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. Br J Health Psychol 2004; 9: 53355.
  • 41
    Kitchener HC, Burns S, Nelson L, Myers AJ, Fletcher I, Desai M, Dunn G, Maguire P. A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. Br J Obstet Gynaecol 2004; 111: 6370.
  • 42
    Bulkmans NW, Berkhof J, Bulk S, Bleeker MCG, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. Differences in clearance rates of 14 hr-HPV types in large-scale population-based cervical screening. In: Monsonego J, ed. Eurogin Conference Proceedings, Paris, Palais des congres, April 23–26, 2006. 71.
  • 43
    Bos AB, van Ballegooijen M, van Oortmarssen GJ, van Marle ME, Habbema JD, Lynge E. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997; 75: 12430.